Advanced search for publications
Enter your keywords
NHS Medicines Optimisation Opportunities Dashboard 2023-24
At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver […]
Drugs for Dementia
This report looks at prescribing trends in primary care for Drugs for Dementia at SICBL and ICB level with particular focus on low strength antipsychotics. Prescribing data is weighted with QOF registers. If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net Frequency Quarterly Data Period July 2020 to […]
Budget impact of paracetamol 250mg/5ml oral suspension
The purpose of this bulletin is to highlight the increase in cost of paracetamol 250mg/5ml oral suspensions since May 2022. It considers the potential savings that could be achieved through cost-effective paracetamol suspension prescribing across the ICSs in the North East & Yorkshire region and Greater Manchester.
Budget impact of promethazine prescribing
The purpose of this bulletin is to highlight the rapid NHS price increase of promethazine hydrochloride tablets since July 2022, and to raise awareness of the impact the price increase is having on ICB prescribing budgets. Potential alternative options are outlined, to reduce prescribing costs. The bulletin considers the potential budget impact to primary care […]
Access to opioids in Urgent and Emergency Care settings in NENC ICS – GNPRC 2023
This poster was first presented at the Great North Pharmacy Research Collaborative in July 2023. It investigates access to opioids in UEC settings to identify trends, variations, and areas of good practice; find the poster and abstract below. Download the poster here.
Budget impact of methylphenidate modified release tablet choice
The purpose of this bulletin is to highlight the difference in cost between bioequivalent methylphenidate modified release (MR) tablets. It considers the budget impact of MR tablet choice and shows the yearly primary care spend on all methylphenidate XL tablets, and the proportion of this spend on each of the available brands.
NICE TA875; Semaglutide for managing obesity: A briefing for ICSs
In March 2023 NICE published TA875: Technology Appraisal guidance for semaglutide (Wegovy®) for managing overweight and obesity. The guidance recommends semaglutide as an option for weight management when prescribed by a specialist service alongside a reduced-calorie diet and increased physical activity in adults if they meet the criteria specified. This briefing aims to provide advice […]
Polypharmacy & Overprescribing: Opioid population health management
In recent years, there has been increasing concern regarding the overprescribing of opioids and associated harms. The RDTC has produced a series of publications as part of the Polypharmacy and Overprescribing theme reviewing opioid prescribing: Each publication includes considerations and interventions for medicines optimisation teams and health systems. To avoid duplication across this series of […]
Polypharmacy & Overprescribing: Opioid patient demographics
In recent years, there has been increasing concern regarding the overprescribing of opioids and associated harms. The RDTC has produced a series of publications as part of the Polypharmacy and Overprescribing theme reviewing opioid prescribing: Each publication includes considerations and interventions for medicines optimisation teams and health systems. To avoid duplication across this series of […]
Polypharmacy & Overprescribing: Opioid patient populations
In recent years, there has been increasing concern regarding the overprescribing of opioids and associated harms. The RDTC has produced a series of publications as part of the Polypharmacy and Overprescribing theme reviewing opioid prescribing: Each publication includes considerations and interventions for medicines optimisation teams and health systems. To avoid duplication across this series of […]